. cIMP synthesized by sGC as a mediator of hypoxic contraction of coronary arteries. Am J Physiol Heart Circ Physiol 307: H328 -H336, 2014. First published June 6, 2014; doi:10.1152/ajpheart.00132.2014cGMP is considered the only mediator synthesized by soluble guanylyl cyclase (sGC) in response to nitric oxide (NO). However, purified sGC can synthesize several other cyclic nucleotides, including inosine 3=,5=-cyclic monophosphate (cIMP). The present study was designed to determine the role of cIMP in hypoxic contractions of isolated porcine coronary arteries. Vascular responses were examined by measuring isometric tension. Cyclic nucleotides were assayed by HPLC tandem mass spectroscopy. Rho kinase (ROCK) activity was determined by measuring the phosphorylation of myosin phosphatase target subunit 1 using Western blot analysis and an ELISA kit. The level of cIMP, but not that of cGMP, was elevated by hypoxia in arteries with, but not in those without, endothelium [except if treated with diethylenetriamine (DETA) NONOate]; the increases in cIMP were inhibited by the sGC inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ). Hypoxia (PO2: 25-30 mmHg) augmented contractions of arteries with and without endothelium if treated with DETA NONOate; these hypoxic contractions were blocked by ODQ. In arteries without endothelium, hypoxic augmentation of contraction was also obtained with exogenous cIMP. In arteries with endothelium, hypoxic augmentation of contraction was further enhanced by inosine 5=-triphosphate, the precursor for cIMP. The augmentation of contraction caused by hypoxia or cIMP was accompanied by increased phosphorylation of myosin phosphatase target subunit 1 at Thr 853 , which was prevented by the ROCK inhibitor Y-27632. ROCK activity in the supernatant of isolated arteries was stimulated by cIMP in a concentration-dependent fashion. These results demonstrate that cIMP synthesized by sGC is the likely mediator of hypoxic augmentation of coronary vasoconstriction, in part by activating ROCK. soluble guanylyl cyclase; inosine 3=,5=-cyclic monophosphate; hypoxic vasoconstriction; endothelium A PREVIOUS STUDY reported that acute hypoxia caused a rapid further increase in tension of contracted canine saphenous veins (31). Subsequent findings demonstrated that such a phenomenon, termed hypoxic augmentation of vasoconstriction (5, 15), occurs in a number of blood vessel types (5, 7, 8, 15, 21, 23, 25, 26) contracted with norepinephrine (7, 8), phenylephrine (23), PGF 2␣ (15, 25) , and the TP receptor agonist U-46619 (21), indicating that it is not unique for a specific vasoconstrictor. It occurs in isolated coronary arteries with but not without endothelium (5, 15, 25, 26) . The phenomenon is not affected by bosentan, a blocker of endothelin receptors (5), but is prevented by inhibitors of nitric oxide (NO) synthase (5, 15, 25) . Hypoxic augmentation also occurs in arteries without endothelium treated with an exogenous NO donor (5) However, hypoxic augmentation is not accompanied by changes in the intracellular level of cGMP. Likewise, a cell-permeable analog of cGMP or elevation of intracellular cGMP levels with atrial natriuretic peptide is ineffective in restoring the phenomenon in rings without endothelium (5).
A PREVIOUS STUDY reported that acute hypoxia caused a rapid further increase in tension of contracted canine saphenous veins (31) . Subsequent findings demonstrated that such a phenomenon, termed hypoxic augmentation of vasoconstriction (5, 15) , occurs in a number of blood vessel types (5, 7, 8, 15, 21, 23, 25, 26) contracted with norepinephrine (7, 8) , phenylephrine (23) , PGF 2␣ (15, 25) , and the TP receptor agonist U-46619 (21) , indicating that it is not unique for a specific vasoconstrictor. It occurs in isolated coronary arteries with but not without endothelium (5, 15, 25, 26) . The phenomenon is not affected by bosentan, a blocker of endothelin receptors (5), but is prevented by inhibitors of nitric oxide (NO) synthase (5, 15, 25) . Hypoxic augmentation also occurs in arteries without endothelium treated with an exogenous NO donor (5) and is prevented by inhibitors of soluble guanylyl cyclase (sGC), including methylene blue, 1H-[1,2,4]oxadiazolo [4,3, -a]quinoxalin-1-one (ODQ), and NS-2028 (5, 15) . Incubation with activators of sGC (YC-1 and Bay 412272) in arteries without endothelium also restores the hypoxic augmentation of vasoconstriction, indicating a critical role of sGC (5) . However, hypoxic augmentation is not accompanied by changes in the intracellular level of cGMP. Likewise, a cell-permeable analog of cGMP or elevation of intracellular cGMP levels with atrial natriuretic peptide is ineffective in restoring the phenomenon in rings without endothelium (5) .
The formation of non-cGMP nucleoside 3=,5=-cyclic monophosphates by sGC in mammalian tissues has been suspected years ago (14) . Due to insufficient sensitivity and specificity of the detection methods, it has only recently become obvious that sGC possesses much broader substrate specificity than previously assumed (4) . Thus, using a highly sensitive and specific HPLC tandem mass spectrometry (HPLC-MS/MS) method, Seifert and colleagues (4) demonstrated that, in addition to cGMP, purified rat sGC can generate six different cyclic nucleotides. Among them, the formation rate of inosine 3=,5=-cyclic monophosphate (cIMP) is substantially greater than that of the other cyclic nucleotides except cGMP (4) . The present study was designed to determine whether or not cIMP may act as the mediator for the above-mentioned endothelium-dependent hypoxic augmentation of vasoconstriction.
MATERIALS AND METHODS
Agents. The following drugs were used (unless otherwise specified, all were obtained from Sigma, St. Louis, MO): Bay 58-2667 (Adipogen, San Diego, CA), 8-bromo-cGMP, diethylenetriamine (DETA) NONOate (Cayman Chemical, Ann Arbor, MI), cGMP, indomethacin, cIMP, inosine 5=-diphosphate (IDP), inosine 5=-monophosphate (IMP), inosine 5=-triphosphate (ITP), ODQ, nitro-L-arginine, pyridoxalphosphate-6-azo-phenyl-2=,4=-disulphonic acid (PPADS), tenofovir (Santa Cruz Biotechnology, Santa Cruz, CA), U-46619, and Y-27632. Indomethacin was prepared in equimolar Na 2CO3. DETA NONOate was dissolved in 0.01 M NaOH. The concentrations of Na2CO3 and NaOH used did not significantly affect the pH of the solution. ODQ was dissolved in DMSO (final concentration: Ͻ0.01%). The other agents were prepared in distilled water.
Tissue preparations. Fresh porcine hearts were collected within 30 min of death from a local slaughterhouse in ice-cold oxygenated modified Krebs-Ringer bicarbonate solution [hereafter referred to as Krebs solution; composed of (in mM): 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, and 11.1 glucose]. The left anterior descending and left and right circumflex coronary arteries were dissected and cut into rings (3 mm long, 2.5-mm diameter) in ice-cold Krebs solution. The endothelium of some rings was removed by gently rubbing the luminal surface with the tips of a watchman's forceps. Removal of endothelium was confirmed by lack of relaxation to bradykinin (3 ϫ 10 Ϫ7 M) (33 Ϫ7 M for arteries with endothelium or those without endothelium treated with DETA NONOate; 2 ϫ 10 Ϫ8 M for other groups) was added. In some experiments, DETA NONOate or ITP were administrated 15 min before the administration of U-46619. Thirty minutes after the administration of U-46619, preparations were exposed to hypoxia (95% N2-5% CO2, PO2: 25-30 mmHg) for 3 min. Tissues were snap frozen immediately before the administration of U-46619, after 30 min of exposure to the thromboxane A2 mimetic, or 3 min after exposure to hypoxia. Frozen tissue (200 -400 mg) was dissolved and homogenized in 100% methanol (containing 10 ng/ml tenofovir as an internal standard) and centrifuged (12,000 g, 20 min, 4°C). The supernatant was dried using Termovap Sample Concentrator, dissolved in 120 l H2O, and filtered with a 0.22-m filter for ultra-performance liquid chromatography (UPLC)-MS/MS. Cyclic nucleotides were separated using an ACQUITY UPLC system (Waters, Milford, MA) equipped with a binary pump system, a degasser, and a temperature-controlled autosampler. After the injection of 10 l, analytes were separated using a column saver (0.2-m filter, ASSY, FRIT, Waters) and a BEH-C18 column (50 ϫ 2.1 mm, 1.7 m, Waters) at 25°C. Eluent A was MilliQ pure water containing 10 mM ammonium acetate and 0.1% (vol/vol) acetic acid, and eluent B was methanol containing 0.1% (vol/vol) acetic acid. The gradient started with 97% of eluent A and 3% of eluent B for 1 min, and the fraction of eluent B was then raised to 15% in 1 min, held for 1.5 min, restored to starting conditions in 1 min, and held for 30 s. The total runtime was 5 min. The flow rate was 0.3 ml/min.
Mass detection was performed on a Qtrap 5500 mass spectrometer (AB Sciex, Foster City, CA) using multiple selected ion monitoring (MRM) analysis in positive ionization mode. The multiple selected ion monitoring transitions were detected with a 50-ms dwell time. Ion source settings and collision gas pressure were manually optimized (curtain gas ϭ 40 psi, nebulizing gas ϭ 30 psi, auxiliary gas ϭ 30 psi, ion source voltage ϭ 5,500 V, collision-activated dissociation energy ϭ medium, temperature ϭ 400°C). Data were acquired and analyzed with Analyst (version 1.5.1, AB Sciex). Table 1 shows the parameters for the detection and identification of cIMP and cGMP.
Isometric tension experiments. Rings of coronary arteries were suspended in organ chambers filled with 8 ml Krebs solution. Two stirrups were passed through the lumen. One stirrup was anchored to the bottom of the organ chamber, and the other stirrup was connected to a strain gauge. Isometric force was measured with a ML785 PowerLab/8sp recording and analysis system (AD Instruments, Castle Hill, Sydney, Australia). The organ chamber solution was aerated with 95% O2-5% CO2 (PO2: 400 mmHg) and maintained at 37 Ϯ 0.1°C and pH at 7.4. Arterial smooth muscle senses the change in the absolute amount of O2 rather than PO2 (17) . Under in vivo conditions, O2 supplied by the blood is carried mainly by hemoglobin, whereas in vitro O 2 available in the organ chamber totally depends on physical dissolution. If O2 tension is set at a PO2 of 100 mmHg to mimic the in vivo conditions, the O2 content in the bath solution may be insufficient to sustain normal vasoconstriction (22) . Thus, for rings of porcine coronary arteries as used in the present study, the maximal contraction evoked by U-46619 (10 Ϫ6 M) was significantly less when the organ chamber was aerated with 20% O2 (PO2: 140 mmHg) compared with 95% O2 (3.3 Ϯ 1.4 vs. 12.3 Ϯ 1.5 g, n ϭ 7, P Ͻ 0.05). Hence, 95% O2-5% CO2 was used as the control aeration mixture in the present experiments.
At the beginning of the experiment, each blood vessel ring was stretched to its optimal resting tension (ϳ2.5 g) by stepwise stretching until the active contraction to 100 mM KCl reached a plateau. After 30 min of equilibration, various pharmacological inhibitors [indomethacin, nitro-L-arginine, ODQ, Y-27632, or PPADS (a P2Y purinoceptor antagonist) (28)] or solvents were added. Thirty minute after the addition of these inhibitors, arteries were contracted with U-46619. In some experiments, DETA NONOate, 8-bromo-cGMP, cIMP, or ITP was added 15 min before U-46619. The contraction caused by U-46619 usually reached steady state within 30 min. Arteries not able to sustain contraction to the thromboxane agonist were discarded. When the contraction to U-46619 had stabilized, the response of the arteries to hypoxia was determined by exposing tissues to a gas mixture of 95% N 2-5% CO2 (PO2: 25-30 mmHg) for 10 min (Fig. 1) .
Cell membrane permeability of cIMP. Rat aortic smooth muscle cells were cultured as previously described (19) . The cell membrane permeability of exogenous cIMP was determined by incubating cultured cells in 5 ml DMEM without serum containing cIMP at 3 ϫ 10 Ϫ4 M at 37°C for 30 min. Cells were then washed three times with cold PBS, collected in 1 ml of 100% methanol (containing 10 ng/ml tenofovir as an internal standard), sonicated three times (for 5 s), and centrifuged (12,000 g for 20 min at 4°C). Concentrations of cIMP in the incubation solution and supernatant were determined by HPLC-MS/MS as described above. To calculate intracellular cIMP concentrations, an average volume of 200 l/rat aortic smooth muscle cell was accepted (24) .
Western blot analysis. Blood vessel rings were incubated in control solution in the presence of indomethacin (10 Ϫ5 M) with and without Y-27632 (10 Ϫ5 M). After 30 min of equilibration, U-46619 (2 ϫ 10 Ϫ8 -3 ϫ 10 Ϫ7 M) was administrated. Thirty minutes later, preparations were exposed to hypoxia for 1-3 min and then snap frozen. In some experiments, cIMP was administrated 30 min before hypoxia. Frozen tissues were homogenized in lysis buffer containing 34.67 mM SDS, 1 mM sodium orthovanadate, and 10 mM Tris base (pH 7.4). Homogenates ϩ , quantifier and qualifier tandem mass spectroscopy (MS/MS) fragments, quantifier-to-qualifier ratios, and HPLC retention times for cGMP, inosine 3=,5=-cyclic monophosphate (cIMP), and tenofovir are shown. m/z, mass-to-charge ratio. Tenofovir was used as a MS standard.
were centrifuged at 12,000 g for 30 min. Supernatants, each containing 20 g protein, were subjected to SDS-PAGE and electrotransferred to polyvinylidene fluoride membranes. The blot was incubated with antibody against phosphorylated myosin phosphatase target subunit 1 (MYPT1) at Thr 853 (Cell Signaling Technology, Beverly, MA, 1:1,000 dilution) and MYPT1 (BD Biosciences, San Diego, CA, 1:1,000 dilution) overnight at 4°C, respectively. Afterward, the blot was developed using the chemiluminescence detection method (SuperSignal West Pico Chemiluminescent Substrate, Thermo Fisher Scientific, Rockford, IL). Protein levels of blots were quantified by densitometry using a Gel Doc 2000 densitometer (Bio-Rad). Phosphorylation of MYPT1 was determined by the ratio of the protein level of phosphorylated MYPT1 at Thr 853 over that of total MYPT1 (33) . Rho kinase assay. Porcine coronary arteries dissected as described above were homogenized in lysis buffer containing 50 mM Tris·HCl (pH 8.0), 0.1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 0.5 mM PMSF, 10 mM NaF, 2 mM Na 3VO4, and 10 mM ␤-mercaptoethanol. Lysates were centrifuged at 12,000 g for 30 min. Supernatants were obtained, and samples containing 10 g protein were mixed with cIMP (3 ϫ 10 Ϫ8 -3 ϫ 10 Ϫ6 M) or solvent with and without Y-27632 (10 Ϫ5 M) immediately before the assay. Rho kinase (ROCK) activity was measured using a Rho-kinase Assay Kit (catalog no. CY-1160, CycLex, Nagano, Japan) according to the manufacturer's instructions. ROCK activity is expressed as milliunits per microgram of protein with CyLex ROCK positive control (CY-E1160-1) as a reference.
HPLC assay of ITP. Isolated porcine coronary arteries with endothelium were equilibrated for 30 min in control solution aerated with 95% O 2-5% CO2 (pH 7.4, 37°C) followed by the addition of indomethacin (10 Ϫ5 M). Thirty minutes later, U-46619 (10 Ϫ7 M) was administrated. After 30 min, arteries were exposed to hypoxia for 3 min and quickly frozen in liquid nitrogen. The frozen tissue (400 -500 mg) was dissolved and homogenized in methanol, sonicated three times (for 5 s), and centrifuged (12,000 g, 15 min, 4°C). The supernatant was dried using Termovap Sample Concentrator, dissolved in 100 l H 2O, and centrifuged twice (12,000 g, 10 min, 4°C) for HPLC.
Ten microliters of the supernatant were injected onto a column (Scherzo SW-C18, 150 ϫ 3 mm, 3 m, Imtakt). The mobile phase consisted of 50 mmol/l potassium dihydrogen phosphate and 50 mmol/l dipotassium hydrogen phosphate buffer (pH 3.8), used in isocratic mode. The flow rate was 0.5 ml/min, and the detection wavelength was set at 254 nm using a photodiode array detector. All analyses were performed at ambient temperature. Peak identity was confirmed by comparison with the standard. Calculations were made in external standard mode using peak-area ratios (6) . The intracellular content of ITP is expressed as picomoles per milligram of protein.
Data analysis. Data are shown as means Ϯ SE; in all experiments, n is the number of animals. Contractions to U-46619 are expressed in grams. Hypoxic responses were evaluated by measuring the area under the isometric tension trace of the first 3 min of hypoxia over that of the last 3 min of stable contraction to U-46619 before hypoxia. Student's t-test for unpaired observations was used to compare the mean values of two groups. Mean values of more than two groups were compared using one-way ANOVA with the Student-NewmanKeuls test for post hoc testing of multiple comparisons. Statistical significance was accepted when the P value (two tailed) was Ͻ0.05.
RESULTS
cIMP assay. Basal levels of intracellular cIMP were similar in porcine coronary arteries with and without endothelium and those treated with ODQ, a selective sGC inhibitor. The basal level of cGMP was significantly greater in arteries with endothelium than in those without endothelium and in arteries with endothelium treated with ODQ (Fig. 2, C and D) .
Basal levels of cIMP and cGMP were not affected by U-46619 (Fig. 2, C-F) . In the presence of U-46619, hypoxia (25-30 mmHg) significantly increased the cIMP level but had no significant effect on that of cGMP in arteries with endothelium (Fig. 2, A-D) . cIMP levels were also increased in arteries without endothelium exposed to DETA NONOate and in arteries with endothelium exposed to ITP, the substrate for cIMP synthesis (4). Under both conditions, cIMP levels were increased further by hypoxia. These changes in cIMP levels were inhibited by ODQ (Fig. 2, E and F) . Bay 58-2667 (10 Ϫ6 M), a heme-independent activator of sGC (10), did not affect cIMP levels of arteries without endothelium under control conditions. In the presence of Bay 58-2667, the cIMP level of arteries was significantly greater after hypoxic exposure compared with control (206.9 Ϯ 22.7 vs.134 Ϯ 27.5 pmol/mg protein, n ϭ 4 -5, P Ͻ 0.05).
Isometric tension. Isolated coronary arteries were contracted with U-46619 to similar tension levels (ranging from 8.94 Ϯ 0.5 to 10.58 Ϯ 0.7 g, n ϭ 15-18 for each group, P Ͼ 0.05). In arteries with endothelium contracted with U-46619, hypoxia caused a transient further contraction that peaked within 3 min followed by relaxation. In arteries with endothelium treated with nitro-L-arginine [10 Ϫ4 M, an inhibitor of endothelial NO synthase (11)] or arteries without endothelium, hypoxia caused only relaxation that did not reach steady state during the 10 min of exposure.
The absence of hypoxic contraction in arteries denuded of endothelium was restored by DETA NONOate (10 Ϫ5 M) but not 8-bromo-cGMP (3 ϫ 10 Ϫ4 M); the restoration was prevented by ODQ (3 ϫ 10 Ϫ5 M; Fig. 3, B and E) . The augmentation was also restored by Bay 58-2667 (10 Ϫ6 M), as evidenced by the observations that hypoxia caused a further contraction of arteries without endothelium treated with the heme-independent activator of sGC but relaxation of control Thirty minutes later, arteries were contracted with U-46619. Thirty minutes after the administration of U-46619, arteries were exposed to hypoxia (95% N2-5% CO2, PO2: 25-30 mmHg) for 10 min (A). In some experiments, diethylenetriamine (DETA) NONOate (NO), 8-bromo-cGMP (8-Br-cGMP), inosine 3=,5=-cyclic monophosphate (cIMP), or inosine 5=-triphosphate (ITP) was added 15 min before U-46619 (B). Experimental protocols for HPLC tandem mass spectrometry (MS/MS) quantitation of cIMP and cGMP were similar as described above except that 8-Br-cGMP and cIMP were not used and that arteries were exposed to hypoxia for 3 min. vessels (hypoxic response expressed as the percentage of contraction to 3 ϫ 10 Ϫ8 M U-46619: 28.7 Ϯ 6.0 vs. Ϫ5.7 Ϯ 2.6, n ϭ 4, P Ͻ 0.05).
In arteries without endothelium, hypoxic augmentation was reinstalled by cIMP, in a concentration-dependent manner, starting at 10 Ϫ4 M (Fig. 3, C and F) . Treatment with cIMP did not significantly affect the relaxation phase of the response to hypoxia [maximal magnitude of the relaxation after 10 min of hypoxia averaged 79.6 Ϯ 4.6% (n ϭ 9) of the tension evoked by 3 ϫ 10 Ϫ8 M U-46619 in the cIMP-treated group, a value not significantly different from control (75.8 Ϯ 2.7%, n ϭ 9, P Ͼ 0.05)]. To estimate the intracellular penetration of cIMP when applied extracellularly, cultured rat aortic smooth muscle cells were incubated with 3 ϫ 10 Ϫ4 M cIMP for 30 min. The subsequent calculation based on HPLC-MS/MS assay results indicated that the intracellular level of cIMP averaged 3.4 Ϯ 0.2 ϫ 10 Ϫ6 M (n ϭ 5). In arteries with endothelium, the hypoxic augmentation effect was further enhanced by the addition of ITP, and this was abolished by ODQ (Fig. 3, D and G) . ITP and cIMP were administrated before arteries were contracted with U-46619 under basal conditions and in the presence of PPADS (10 Ϫ5 M) to prevent a possible activation of P2Y purinoceptors (27) . At the concentration tested (3 ϫ 10 Ϫ4 M), ITP or cIMP did not significantly affect basal tension (n ϭ 6, P Ͼ 0.05).
In U-46619-contracted porcine coronary arteries without endothelium treated with DETA NONOate or cIMP, exposure to hypoxia caused a further increase in tension, which was significantly attenuated by the ROCK antagonist Y-27632 ( Western blot analysis. In arteries both with and without endothelium, the vasoconstrictor U-46619 increased the phosphorylation of MYPT1 at Thr
853
. Hypoxia caused further phosphorylation of MYPT1 not only in arteries with endothelium but also in those without endothelium treated with cIMP. Hypoxic responses were abolished by Y-27632 (Fig. 4, A-E) .
ROCK activity. Under control conditions, ROCK activity of the supernatant of porcine coronary arteries averaged 0.40 Ϯ 0.02 mU/g protein (n ϭ 6). ROCK activity was stimulated significantly and concentration dependently by cIMP (10 was reduced below the control level, irrespective of the presence of cIMP (Fig. 5) . ITP assay. HPLC showed that under control conditions, the ITP content of the supernatant of porcine coronary arteries averaged 171.9 Ϯ 35.9 pmol/mg protein (n ϭ 4) and that this was significantly augmented by 3 min of exposure to hypoxia (489.4 Ϯ 56.5 pmol/mg protein, n ϭ 5, P Ͻ 0.05; Fig. 6 ).
DISCUSSION
Previous work has shown that hypoxia causes endotheliumdependent augmentation of contractions of isolated coronary arteries that require endogenous NO, the primary activator of sGC (5, 15, 23, 25) . Such augmentation is inhibited by ODQ, which inhibits sGC via oxidation of the prosthetic heme group of sGC (10) , but also by other inhibitors of the enzyme (5, 15) . The phenomenon also occurred in arteries treated with YC-1 and Bay 412272, which activate sGC without the interaction with the heme moiety (5) . In the present study, Bay 58-2667, a heme-independent activator of sGC (10), also restored hypoxic augmentation of vasoconstriction in arteries without endothelium. These results provide further support for a critical role of sGC in the hypoxia-induced further increases in tension. It should be noted that, although the hypoxic conditions in the present study were obtained with 95% N 2 -5% CO 2 , evidence suggests that endothelium-dependent and sGC-dependent augmentation of vasoconstriction occurs when arteries are exposed to hypoxia obtained with a gas mixture containing either 0%, 5%, or 10% O 2 (5, 15, 23, 26) . cGMP is considered the sole second messenger mediating the actions of sGC (11, 12) . However, results from the present and previous studies have demonstrated that the endotheliumdependent hypoxic augmentation of vasoconstriction is not associated with a significant change in the intracellular cGMP level (5, 15) . The presence of the endothelium or of NO is not mimicked by increasing the intracellular content of the cyclic nucleotide by administering a cell-permeable analog (Ref. 5 and the present study), by stimulating particulate guanylyl cyclase (with atrial neuropeptides) (5), or by inhibiting its degradation with an inhibitor of phosphodiesterases (15) . It is not affected by inhibitors of cGMP-dependent protein kinase (5, 15) . Hence, it appears that cGMP signaling does not contribute significantly to this hypoxic response.
In contrast to cGMP, the present results demonstrate that the production of cIMP is markedly augmented by hypoxia in porcine coronary arteries. This augmentation occurred only in arteries with endothelium or in preparations without endothelium treated with a NO donor; it was inhibited by ODQ. Furthermore, an increased cIMP level in response to hypoxia also occurred in arteries without endothelium treated with Bay 58-2667. These results suggest that the increased production of cIMP under hypoxia results from the activation of sGC. Not only did the cIMP level of arteries with endothelium (or of denuded arteries treated with a NO donor) increase during hypoxia, but it also was elevated in intact arteries when exposed under control conditions to the cIMP precursor ITP, with a further increase when the PO 2 was reduced. These observations imply that hypoxia increases the availability of ITP. Indeed, the HPLC assay showed an augmented intracellular level of ITP when porcine coronary arteries were made hypoxic. ITP is primarily derived from ATP deamination (3, 27) . Exogenous ATP potently elevates endogenous cIMP (9) . ATP is the most abundant nucleotide, with an intracellular concentration in the low millimolar range (16) . It is estimated that ϳ10 -25% of the ATP pool can be converted to ITP by deamination (27) . Under normal conditions, ITP is largely degraded by ITPase, and the intracellular level of ITP is rather low. When the enzyme is inhibited or defective, the ITP level is increased (3, 29) . Therefore, if hypoxia suppresses the activity of ITPase, sufficient ITP could accumulate for sGC to synthesize cIMP (2) .
An important role for cIMP in hypoxic-augmented vasoconstriction is supported by the finding that this phenomenon was restored by exogenous cIMP in artery without endothelium or its precursor ITP in arteries with endothelium. Cyclic nucleotides diffuse across the cell membrane only to a limited extent, but both cIMP and ITP may cross the cell membrane using equilibrative nucleoside transporters (20) . The present HPLC-MS/MS assay showed that ϳ1% of the cIMP present extracellularly can diffuse into cells. Thus, when applied exogenously, at concentrations that were effective to prompt the hypoxic augmentation of vasoconstriction (Ն10 Ϫ4 M), the intracellular levels of the cyclic nucleotide obtained (Ն10 Ϫ6 M) are likely to be sufficient to activate its target enzymes. In arteries with endothelium, the hypoxic augmentation of contraction was further enhanced by exogenous ITP. The effect of ITP was prevented by ODQ, indicating that it acts intracellularly as a substrate for sGC. The hypoxic augmentation of vasoconstriction is attenuated by the ROCK inhibitors Y-27632 and HA-1077, implying that it results from the activation of ROCK (5) . The present study confirms and demonstrates, respectively, that the hypoxic potentiation obtained with exogenous NO and cIMP is prevented by Y-27632. The phosphorylation of MYPT1 at Thr 853 caused by ROCK leads to reduced dephosphorylation of myosin light chain and subsequently increased vasoconstriction (13, 30) . The Y-27632-inhibitable phosphorylation of MYPT1 at Thr 853 has therefore been used as an indicator of the activity of ROCK (13, 30) . In the present study, although MYPT1 was phosphorylated by the vasoconstrictor U-46619 in all preparations studied, hypoxia caused Y-27632-inhibitable further phosphorylation of MYPT1 only in arteries with endothelium and rings without endothelium treated with cIMP, suggesting that the cyclic nucleotide promotes hypoxic vasoconstriction at least in part via the activation of ROCK (5) . Moreover, the present assay demonstrates that Y-27632-inhibitable ROCK activity in supernatants from coronary arteries is stimulated by cIMP at concentrations at least 100-fold lower than those applied extracellularly. These observations provide strong evidence supporting the interpretation that cIMP acts as an intracellular mediator of hypoxic augmentation of vasoconstriction by activating ROCK.
The present experiments were performed on large coronary arteries, which normally do not contribute importantly to coronary vascular resistance. However, they are major sites where vasospasm occurs resulting in symptoms of myocardial ischemia (1) . A previous in vivo study (25) demonstrated that, after ischemia-reperfusion injury, hypoxemia causes constrictions of epicardial arteries that can be prevented by an inhibitor of NO synthase, which is line with the present assumption that cIMP synthesized by NO-activated sGC mediates hypoxic vasoconstriction. The NO-cGMP signaling pathway is functional along the coronary vascular tree (18, 33) . Whether or not cIMP contributes to hypoxic responses of resistance arteries remains to be determined.
